Abstract
The demands of social distancing during the novel coronavirus 2019 (COVID-19) pandemic have upended standard healthcare workflows through travel limitations, site closures, and interruptions of medication supply chains (U.S. Food & Drug Administration, 2020). These changes have impacted the conduct of highly choreographed clinical trials, which require timely visits and assessments to maintain scientific validity in evaluating the safety and efficacy of new medications (European Medicines Agency, 2020; U.S.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
